Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 2
2006 2
2007 1
2008 2
2010 1
2012 1
2013 1
2016 4
2017 4
2018 9
2019 7
2020 4
2021 7
2022 6
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean xiaojian yu (10 results)?
Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.
Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W, Seery S, Zhang Y, Peng S, Xu J, Duan J, Wang Z, Yu X, Zheng Q, Xu X, Yuan Y, Yan F, Tian Z, Tang K, Zhang J, Chang AH, Feng X. Pan J, et al. Among authors: yu x. J Clin Oncol. 2021 Oct 20;39(30):3340-3351. doi: 10.1200/JCO.21.00389. Epub 2021 Jul 29. J Clin Oncol. 2021. PMID: 34324392 Clinical Trial.
Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.
Pan J, Tang K, Luo Y, Seery S, Tan Y, Deng B, Liu F, Xu X, Ling Z, Song W, Xu J, Duan J, Wang Z, Li C, Wang K, Zhang Y, Yu X, Zheng Q, Zhao L, Zhang J, Chang AH, Feng X. Pan J, et al. Among authors: yu x. Lancet Oncol. 2023 Nov;24(11):1229-1241. doi: 10.1016/S1470-2045(23)00436-9. Epub 2023 Oct 17. Lancet Oncol. 2023. PMID: 37863088 Clinical Trial.
A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma.
Espinoza AF, Patel RH, Patel KR, Badachhape AA, Whitlock R, Srivastava RK, Govindu SR, Duong A, Kona A, Kureti P, Armbruster B, Kats D, Srinivasan RR, Dobrolecki LE, Yu X, Najaf Panah MJ, Zorman B, Sarabia SF, Urbicain M, Major A, Bissig KD, Keller C, Lewis MT, Heczey A, Sumazin P, López-Terrada DH, Woodfield SE, Vasudevan SA. Espinoza AF, et al. Among authors: yu x. J Hepatol. 2024 Apr;80(4):610-621. doi: 10.1016/j.jhep.2024.01.003. Epub 2024 Jan 17. J Hepatol. 2024. PMID: 38242326
Navigating relapsed hepatoblastoma: Predictive factors and surgical treatment strategy.
Espinoza AF, Patel KR, Shetty PB, Whitlock RS, Sumazin P, Yu X, Sarabia SF, Urbicain M, Heczey A, Masand P, Woodfield SE, López-Terrada DH, Vasudevan SA. Espinoza AF, et al. Among authors: yu x. Cancer Med. 2023 Dec;12(23):21270-21278. doi: 10.1002/cam4.6705. Epub 2023 Nov 14. Cancer Med. 2023. PMID: 37962078 Free PMC article.
A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL.
Tan Y, Cai H, Li C, Deng B, Song W, Ling Z, Hu G, Yang Y, Niu P, Meng G, Cheng W, Xu J, Duan J, Wang Z, Yu X, Feng X, Zhou J, Pan J. Tan Y, et al. Among authors: yu x. Blood Cancer J. 2021 Apr 10;11(4):71. doi: 10.1038/s41408-021-00465-9. Blood Cancer J. 2021. PMID: 33839735 Free PMC article. Clinical Trial. No abstract available.
48 results